News
-
The National Heart, Lung, and Blood Institute of the National Institutes of Health has awarded a 3-year, $3 million grant to Pulmotect for clinical studies of its PUL-042 inhaled therapy for the treatment of respiratory… Read more . . .
-
Approximately 450 OINDP experts gathered May 5-8 in Antibes, France for the 10th anniversary iteration of RDD Europe, which featured scientific presentations and posters, a series of workshops, a technical exhibition, and numerous networking opportunities.… Read more . . .
-
Generex Biotechnology has announced an agreement with NHTherapeutics to co-develop a formulation of leuprolide for delivery by Generex’s RapidMist buccal aerosol technology. Leuprolide is a gonadotropin-releasing hormone (GnRH) analog which is currently approved at higher… Read more . . .
-
According to Boehringer Ingelheim, the FDA has approved its tiotropium bromide/olodaterol soft mist inhaler for the treatment of COPD. The company filed an NDA for the product, which will be marketed as Stiolto Respimat Inhalation… Read more . . .
-
Novartis has announced positive results from several Phase 3 studies of NVA237 glycopyrronium bromide and QVA149 indacaterol/glycopyrronium bromide, both delivered by the Breezhaler DPI for the treatment of COPD. NVA237 is marketed as Seebri Breezhaler… Read more . . .
-
Sunovion Pharmaceuticals has presented results from three studies of Brovana arformoterol tartrate inhalation solution for the treatment of COPD at ATS 2015. According to Sunovion, the studies show that Brovana produces clinically significant improvement in… Read more . . .
-
Boehringer Ingelheim Pharmaceuticals has presented new data analyses from two Phase 3 studies of its tiotropium/olodaterol Respimat SMI for the treatment of COPD at ATS 2015. The two efficacy and safety studies (NCT01431274 and NCT01431287),… Read more . . .
-
Danish inhaled drug developer Serendex has announced that it has met a number of milestones this year in preparation for clinical development of its portfolio. According to Serendex, in the first quarter of 2015, the… Read more . . .
-
Inhaled drug developer Prosonix will be acquired by Circassia Pharmaceuticals for a total of £100 million in cash, the company said. Of that total, £70 million will be paid up front, with an additional £30… Read more . . .
-
Discovery Laboratories has announced that data from a Phase 2a clinical trial of Aerosurf aerosolized KL4 surfactant for the treatment of respiratory distress syndrome (RDS) in premature infants show that the novel delivery technology performed… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland